Irbesartan for the treatment of hypertension in patients with the metabolic syndrome: A sub analysis of the Treat to Target post authorization survey. Prospective observational, two armed study in 14,200 patients

Table 3 Metabolic risk factors in metabolic syndrome patients with Irbesartan treatment alone or in combination with HCTZ

		Irbesartan in patients with the metabolic syndrome¹							Irbesartan/12.5 mg HCT in patients with the metabolic syndrome¹
Components of the Met. Syn.		Baseline		3 months		9 months		Reduction †	Baseline		3 months		9 months		Reduction †
Blood pressure		mean	± SD	mean	± SD	mean	± SD		mean	± SD	mean	± SD	mean	± SD
systolic	mmHg	159.1	± 12.9	137.8*	± 11.2	132.8*	± 10.1	-26.3	161.3	± 13.2	139.0*	± 11.2	133.8*	± 10.1	-27.5
diastolic	mmHg	93.4	± 8.6	82.8*	± 7.2	80.4*	± 6.6	-13.0	95.0	± 8.6	83.8*	± 7.4	80.9*	± 6.6	-14.1
Fasting plasma
glucose	mg/dL	118.3	± 29.9	111.8*	± 26.0	109.9*	± 25.1	-8.4	122.9	± 29.8	115.4*	± 26.0	112.9*	± 24.7	-10.0
Abdominal obesity
men	cm	109.9	± 13.0	108.4*	± 12.2	107.5*	± 11.9	-2.4	112.0	± 12.9	110.3*	± 12.3	108.8*	± 12.7	-3.2
women	cm	99.3	± 14.3	98.3*	± 14.3	98.1*	± 14.2	-1.2	101.5	± 14.7	100.8*	± 14.7	99.8*	± 14.4	-1.7
Triglycerides	mg/dL	212.3	± 61.2	194.2*	± 56.7	183.7*	± 52.1	-28.6	221.5	± 63.0	198.4*	± 55.3	187.4*	± 52.6	-34.1
HDL cholesterol
men	mg/dL	42.2	± 7.7	44.6*	± 7.3	45.8*	± 7.2	3.6	41.4	± 7.5	44.0*	± 7.0	45.4*	± 6.8	4.0
women	mg/dL	45.0	± 7.2	47.8*	± 6.8	48.8*	± 6.5	3.8	44.2	± 7.4	46.4*	± 6.9	47.6*	± 6.8	3.4

¹ doctors' diagnosis; statistical test applied: t-test; * p < 0.0001; ** p < 0.05; † reduction versus baseline

ISSN: 1475-2840